| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Arcus) ARC-6 | A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer | Hotte, Dr Sebastien | Open to recruitment | NCT04381832 |
| (Basilea) DZB-CS-201 / FIDES-02 | An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients wtih urothelial cancer expressing activating molecular FGFR aberrations | Hotte, Dr Sebastien | Open to recruitment | NCT04045613 |
| (CCTG) BL.13 | A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer | Lalani, Dr Aly-Khan | Open to recruitment | NCT03768570 |
| (CCTG) IND.234 / PC-BETS - Master Protocol | Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (Master) |
| (CCTG) IND.234B/PC-BETS Sub-Study B | A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(B) |
| (CCTG) IND.234C/PC-BETS Sub-Study C | A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(C) |
| (CCTG) IND.234D/PC-BETS Sub-Study D | A Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Mukherjee, Dr Som | Open to recruitment | NCT03385655(D) |
| (CCTG) IND.234E/PC-BETS Sub-Study E | A Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA) | Mukherjee, Dr Som | Open to recruitment | NCT03385655(E) |
| (CCTG) IND.234F/PC-BETS Sub-Study F | A Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (F) |
| (CCTG) IND.234G/PC-BETS Sub-Study G | A Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (G) |
| (CCTG) PR.20 | A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON) | Quan, Dr Kimmen | Open to recruitment | NCT03784755 |
| (CHUM) 20.208 / PATRON | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer | Tsakiridis, Dr Theos | Open to recruitment | NCT04557501 |
| (EXELIXIS) XL184-315 / CONTACT-02 | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL 184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy(NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer. | Hotte, Dr Sebastien | Open to recruitment | NCT04446117 |
| (Immunomedics) TROPICS-04 / IMMU-132-13 | A RANDOMIZED OPEN-LABEL PHASE III STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN SUBJECTS WITH METASTATIC OR LOCALLY ADVANCED UNRESECTABLE UROTHELIAL CANCER | Mukherjee, Dr Som | Open to recruitment | NCT04527991 |
| (JCC) The PBS Study | A randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa) | Tsakiridis, Dr Theos | Open to recruitment | NCT03380806 |
| (JGH) PCS IX / PCS 9 | The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial. | Tsakiridis, Dr Theos | Open to recruitment | NCT02685397 |
| (Merck) MK-3475-641 / KEYNOTE 641 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Lalani, Dr Aly-Khan | Open to recruitment | NCT03834493 |
| (OHRI) RADIANT/OTT-19-07/OZM-105 | Neoadjuvant Immune-Modulating Radiation with Durvalumab (MEDI 4736) prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT) | Lalani, Dr Aly-Khan | Open to recruitment | NCT04543110 |
| (Seattle Genetics) SGN22E-003 / EV-302 | An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer | Hotte, Dr Sebastien | Open to recruitment | NCT04223856 |
| (UHN) WI222910 / ALPACA | A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy | Mukherjee, Dr Som | Open to recruitment | NCT03391479 |
| NRG-GU005 / HYPORT | Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer. | Dayes, Dr Ian | Open to recruitment | NCT03367702 |
| OCOG-2013-PETMUSE | Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging | Mukherjee, Dr Som | Open to recruitment | NCT02462239 |
| OCOG-2019-CYTOSHRINK / CA209-7DR | Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer | Lalani, Dr Aly-Khan | Open to recruitment | NCT04090710 |
Find a Trial
Contact Us